Press & Media
Latest News & Breakthroughs
Efficacy and Safety of Magnetic Peripheral Nerve Stimulation for Treatment of Neuropathic Pain; One Year Follow Up of Long-Term Outcomes
A new multi-center study confirms the safety and efficacy of Magnetic Peripheral Nerve Stimulation (mPNS) in treating chronic post-traumatic and post-surgical neuropathic pain. Axon Therapy, combined with Conventional Medical Management (CMM), showed a 71% responder rate at 90 days—with 94% achieving significant pain relief by one year—offering a non-invasive, drug-free alternative for long-term pain reduction.
Neuralace Medical Presents Case Report on Magnetic Peripheral Nerve Stimulation (mPNS) for Back Pain at ASPN Conference
Neuralace Medical presented a compelling case report at the ASPN Annual Conference, highlighting Axon Therapy®—a non-invasive magnetic peripheral nerve stimulation (mPNS) technology—for chronic low back pain. The patient, unresponsive to conventional treatments, experienced a 60% pain reduction and improved function after six sessions. This case reinforces Axon Therapy’s potential as a drug-free, needle-free alternative for disc-related pain and chronic neuropathic conditions.
Neuralace Medical Announces FDA Clearance of Axon Therapy for Chronic Painful Diabetic Neuropathy
Neuralace Medical has received FDA clearance for Axon Therapy®, the first non-invasive magnetic peripheral nerve stimulation (mPNS) treatment for chronic Painful Diabetic Neuropathy (PDN). In clinical trials, Axon Therapy achieved a 72.3% responder rate at 30 days and over 81% by Day 90—offering a drug-free, painless alternative that significantly reduces pain and numbness while improving quality of life.
Neuralace Medical is Set to Showcase its Non-invasive Axon Therapy Using the Company’s Proprietary Magnetic Peripheral Nerve Stimulation Technology (mPNS), at the North American Neuromodulation Society Conference Highlighted by Clinical Presentations in the Areas of Painful Diabetic Neuropathy and Axon Therapy Extended Use Clinical Data
Dr. Lora Brown will present results of the Axon Therapy Painful Diabetic Neuropathy (AT-PDN) study demonstrating the clinical impact of Axon Therapy (mPNS) on patients
Neuralace Medical Completes Enrollment of Painful Diabetic Neuropathy Label Expansion Study (AT-PDN) Paving the Way for FDA Clearance and a Breakthrough, Non-invasive Treatment for Diabetes related Neuropathic Pain
This milestone marks the potential for significant expansion of the clinical benefits of neuromodulation to the millions of patients suffering from PDN who may not be candidates for implantable solutions but can benefit from non-invasive neuromodulation
Neuralace Medical Announces Clinical Milestones Including Presentation of the Safety and Efficacy of Axon Therapy (SEAT) Study at the American Society of Pain and Neuroscience Conference (ASPN), While Completing Enrollment in the Axon Therapy Painful Diabetic Neuropathy Study (AT-PDN) and Launching a Pilot Study Focused on the Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN)
Neuralace Medical will continue to leverage clinical milestone progress to support its current seed fundraising efforts highlighted by a recent first close of $3.1M targeting a total raise of $5-$7M
